Protein Kinase Inhibitors: all 15,278 studies that test it

Page 103 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy VolunteersCompletedNCT03605277Phase 1
• Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid TumorsTerminatedNCT03604783Phase 1
• Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma.Status unknownNCT03602547Phase 2
• A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid CancerTerminatedNCT03602495Phase 3
• Phase I Study of the Combination of Anlotinib With GefitinibStatus unknownNCT03602027Not applicable
• Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
• A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCCStatus unknownNCT03601598Phase 1/2
• XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric AdenocarcinomaStatus unknownNCT03599778Phase 1/2
• Tofacitinib Combined With Chidamide in R/R ENKTCLStatus unknownNCT03598959Phase 2
• Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric CancerStatus unknownNCT03598348Phase 3
• Study Investigating a Single Oral Dose of Fenebrutinib in Healthy VolunteersCompletedNCT03596632Phase 1
• Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line AxitinibStatus unknownNCT03592199Phase 2
• Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Phase 2
• A Study of Anlotinib in Recurrent/Metastatic Head and Neck AdenocarcinomasStatus unknownNCT03591666Phase 2
• A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AMLActive, not recruitingNCT03591510Phase 2
• Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT03589950Phase 2
• INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCompletedNCT03589651Phase 1
• Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesStatus unknownNCT03588598Phase 1
• Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast CancerCompletedNCT03588091Phase 3
• A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of ErdafitinibTerminatedNCT03587363Phase 1
• Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian CancerTerminatedNCT03587129Phase 2
• PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy SubjectsCompletedNCT03586908Phase 1
• Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT03586661Phase 1
• Osimertinib In EGFR Mutant Lung CancerActive, not recruitingNCT03586453Phase 2
• A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E MutationStatus unknownNCT03585686Phase 2
• Efficacy and Safety of Sirolimus to Vascular AnomaliesCompletedNCT03583307Not applicable
• Study of EOC317 in Chinese Patients With Advanced Solid TumorsStatus unknownNCT03583125Phase 1
• Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney TransplantationCompletedNCT03582878Phase 4
• Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)CompletedNCT03581942Phase 1/2
• Apatinib in Neoadjuvant Therapy for Patients With Breast CancerStatus unknownNCT03580395Phase 2/3
• Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway DeficiencyStatus unknownNCT03580239Phase 3
• Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03579316Phase 2
• SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCCCompletedNCT03578874Phase 2
• Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation TherapyTerminatedNCT03578432Early Phase 1
• Liver Transplantation With Tregs at MGHCompletedNCT03577431Phase 1/2
• Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell LymphomaCompletedNCT03576443Phase 2
• Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic KeratosisCompletedNCT03575780Phase 1
• Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity StudyCompletedNCT03575598Early Phase 1
• Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal DystrophyStatus unknownNCT03575130Phase 2
• Phase II Umbrella Study Directed by Next Generation SequencingStatus unknownNCT03574402Phase 2
• A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid CancerCompletedNCT03573960Phase 4
• Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerActive, not recruitingNCT03573648Phase 2
• Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI TreatmentStatus unknownNCT03573596Phase 2
• A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT03571308Phase 1/2
• Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?Status unknownNCT03570437Phase 2
• A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersActive, not recruitingNCT03567642Phase 1
• Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid CancerCompletedNCT03565536Phase 2
• Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).CompletedNCT03564938Phase 4
• Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALLStatus unknownNCT03564470Phase 2/3
• Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)CompletedNCT03564288Phase 1
• Continuation of Nintedanib After Single Lung Transplantation in IPF SubjectsTerminatedNCT03562416Phase 2
• Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationWithdrawnNCT03560908Phase 1
• A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast CancerStatus unknownNCT03560856Phase 2
• The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative NeoplasmStatus unknownNCT03558607Phase 1/2
• Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal CancerCompletedNCT03556956Phase 2/3
• Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448CompletedNCT03556436Phase 1
• Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerCompletedNCT03555877Phase 2
• Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging StudyCompletedNCT03555617Phase 1
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult SubjectsCompletedNCT03554993Phase 1
• A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung CancerCompletedNCT03547804Phase 2
• Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard ChemotherapyStatus unknownNCT03547375Phase 2
• Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.Status unknownNCT03546855Phase 2
• Safety and Efficacy of Anlotinib in Combination With Irinotecan in Patients With Pretreated Advanced Colorectal CancerStatus unknownNCT03545711Phase 1/2
• Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33CompletedNCT03544905Phase 1
• Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant MelanomaActive, not recruitingNCT03543969Early Phase 1
• Apatinib as First -Line Treatment for Advanced Esophagus CancerStatus unknownNCT03542422Phase 2
• Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingNCT03541902Phase 2
• An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram EffectsCompletedNCT03541564Phase 1
• Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS StudyStatus unknownNCT03539172Phase 2
• Bioequivalency Study of Ensartinib Capsules in Healthy VolunteersCompletedNCT03536481Phase 1
• Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast CancerCompletedNCT03535961Phase 2
• Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLCCompletedNCT03535363Phase 1
• Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT03535350Phase 1
• Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaActive, not recruitingNCT03531645Phase 2
• Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating MutationsWithdrawnNCT03529084Phase 3
• Study of Anlotinib in Patients With Primary Malignant Bone TumorsStatus unknownNCT03527888Phase 2
• Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedNCT03527147Phase 1
• Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid TumorsCompletedNCT03525925Phase 1
• A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced MalignanciesTerminatedNCT03522142Phase 1
• A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic CholangiocarcinomaStatus unknownNCT03521219Phase 2
• Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid TumorsCompletedNCT03517956Phase 1
• Expanding Phase III Study of Tyroserleutide for InjectionStatus unknownNCT03516448Phase 3
• Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseActive, not recruitingNCT03516279Phase 2
• EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR MutationsCompletedNCT03516214Phase 1
• A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid TumorsCompletedNCT03516123Phase 1
• A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Phase 2
• Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT03515200Phase 1
• Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and GlioblastomaCompletedNCT03514069Phase 1
• Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsActive, not recruitingNCT03513562Phase 2
• Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingNCT03513484Phase 1
• A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed ConditionsCompletedNCT03512821Phase 1
• A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting ConditionsCompletedNCT03512808Phase 1
• The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma PatientsStatus unknownNCT03511703Phase 2
• A Study of TQ-B3525 on Tolerance and PharmacokineticsStatus unknownNCT03510767Phase 1
• Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular CarcinomaStatus unknownNCT03510416Phase 2
• Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsCompletedNCT03510104Phase 1
• A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive LymphomaCompletedNCT03505554Phase 2
• Tolerance by Engaging Antigen During Cellular HomeostasisCompletedNCT03504241Phase 1
• Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in BangladeshStatus unknownNCT03504072Phase 4
• The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female SubjectsCompletedNCT03502902Phase 1

← Protein Kinase Inhibitors overview